淋巴细胞亚群对乳腺癌新辅助化疗疗效的预测价值

doi:10.3969/j.issn.1009-976X.2021.01.013

摘要/Abstract

摘要： 目的本研究旨在探讨治疗前淋巴细胞亚群对乳腺癌新辅助化疗（NAC）疗效的预测价值。方法本研究选取2016年4月至2020年6月在中山大学孙逸仙纪念医院接受NAC的乳腺癌患者109例。采用卡方检验及logistics回归分析不同淋巴细胞亚群比例与病理完全缓解（pCR）的相关性,并通过Kaplan-Meier曲线评估其与生存时间之间的相关性。同时评估化疗前后T细胞或NK细胞的变化与pCR的关系,并采用免疫组化法检测肿瘤部位T细胞和NK细胞的浸润情况。结果 T细胞比例>71.90%（P=0.044）、NK细胞比例>36.23%（P=0.049）或Ki67增殖指数>62.5%（P=0.010）的患者pCR率较高。在多因素分析中,只有NK细胞比例高（95% CI：0.014~0.736,P=0.024）和Ki67增殖指数高（95% CI：0.083~0.752,P=0.014）才是pCR的预测因素。比较83例患者NAC前后NK细胞的变化,发现NK细胞增多的患者更有可能获得pCR（P=0.031）。此外,治疗前T细胞比例较高的患者,肿瘤浸润性T细胞较多;NK细胞比例较高的患者治疗后,肿瘤浸润性NK细胞较多。结论 NAC前较高比例的T细胞或NK细胞可能表明较好的病理治疗效果。此外,NAC前T细胞和NK细胞的比例也可能与肿瘤部位T细胞和NK细胞的浸润有关。

关键词: 乳腺癌, T细胞, NK细胞, 新辅助化疗, 病理完全缓解

Abstract: Objective Our study was designed to investigate the predictive value of lymphocyte subsets before treatment for the efficacy of neoadjuvant chemotherapy （NAC） in breast cancer. Methods A total of 109 breast cancer patients received NAC in Sun Yat-sen Memorial Hospital, Sun Yat-sen University from April 2016 to June 2020 were enrolled in this study. Chi-square test and logistics regression were used to analyze the correlation between the proportion of different lymphocyte subsets and pathological complete response （pCR）, and Kaplan-Meier curve was used to evaluate the correlation between the lymphocyte subsets and survival time. At the same time, the relationship between the changes of T cells or NK cells before and after chemotherapy and pCR was evaluated, and the infiltration of T cells and NK cells in tumor sites was detected by immunohistochemical method. Results Patients with T cells proportion >71.90% （P=0.044）, NK cells proportion >36.23% （P=0.049） or Ki67 proliferation index >62.5% （P=0.010） showed a higher pCR rate. However, only high NK cells proportion （95% CI： 0.014-0.736, P=0.024） and high Ki67 proliferation index （95% CI： 0.083~0.752, P=0.014） was predictive for pCR in multivariate analysis. Comparing the changes of NK cells before and after NAC in 83 patients, patients with increased NK cells were found more likely to obtain pCR （P=0.031）. In addition, patients with a higher T cells proportion showed more tumor-infiltrating T cells before treatment, and patients with a higher NK cells proportion showed more tumor-infiltrating NK cells after NAC. Conclusion Higher proportion of T cells or NK cells may indicate a better pathological therapeutic efficacy. In addition, the proportion of peripheral T cells and NK cells may also be related to the tumor-infiltrating T cells and NK cells.

Key words: breast cancer, T cell, NK cell, neoadjuvant chemotherapy, pathologic complete response

中图分类号:

R737.9

钟翠玉, 王家维, 黄康玲, 姚燕丹. 淋巴细胞亚群对乳腺癌新辅助化疗疗效的预测价值[J]. 岭南现代临床外科, 2021, 21(01): 74-81.

ZHONG Cui-yu, WANG Jia-wei, HUANG Kang-ling, YAO Yan-dan. Predictive value of lymphocyte subsets for efficacy of neoadjuvant chemotherapy in breast cancer[J]. Lingnan Modern Clinics In Surgery, 2021, 21(01): 74-81.

参考文献

[1] Harbeck N, Gnant M.Breast cancer[J]. Lancet, 2017, 389(10074): 1134-1150.
[2] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.
[3] Spronk PER, Volders JH, van den Tol P, et al. Breast conserving therapy after neoadjuvant chemotherapy; data from the Dutch Breast Cancer Audit[J]. Eur J Surg Oncol, 2019, 45(2): 110-117.
[4] Untch M, Konecny GE, Paepke S, von Minckwitz G. Current and future role of neoadjuvant therapy for breast cancer[J]. Breast, 2014, 23(5): 526-537.
[5] Mayer EL, Carey LA, Burstein HJ.Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer[J]. Breast Cancer Res, 2007, 9(5): 110.
[6] Steenbruggen TG, van Ramshorst MS, Kok M, et al. Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies[J]. Drugs, 2017, 77(12): 1313-1336.
[7] Henderson IC, Berry DA, Demetri GD, et al.Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J]. J Clin Oncol, 2003, 21(6): 976-983.
[8] Fisusi FA, Akala EO.Drug Combinations in Breast Cancer Therapy[J]. Pharm Nanotechnol, 2019, 7(1): 3-23.
[9] Miyashita M, Sasano H, Tamaki K, et al.Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy[J]. Breast Cancer Res Treat, 2014, 148(3): 525-534.
[10] Wimberly H, Brown JR, Schalper K, et al.PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer[J]. Cancer Immunol Res, 2015, 3(4): 326-332.
[11] Darb-Esfahani S, Loibl S, Müller BM, et al.Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy[J]. Breast Cancer Res, 2009, 11(5): R69.
[12] Masuda H, Baggerly KA, Wang Y, et al.Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes[J]. Clin Cancer Res, 2013, 19(19): 5533-5540.
[13] van′t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer[J]. Nature, 2002, 415(6871): 530-536.
[14] Bownes RJ, Turnbull AK, Martinez-Perez C, et al.On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer[J]. Breast Cancer Res, 2019, 21(1): 73.
[15] Andre F, Dieci MV, Dubsky P, et al.Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer[J]. Clin Cancer Res, 2013, 19(1): 28-33.
[16] West NR, Milne K, Truong PT, et al.Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer[J]. Breast Cancer Res, 2011, 13(6): R126.
[17] Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy[J]. Lancet Oncol, 2018, 19(1): 40-50.
[18] Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G.Immunological aspects of cancer chemotherapy[J]. Nat Rev Immunol, 2008, 8(1): 59-73.
[19] Apetoh L, Tesniere A, Ghiringhelli F, et al.Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies[J]. Cancer Res, 2008, 68(11): 4026-4030.
[20] Murta EF, de Andrade JM, Falcão RP, Bighetti S. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy[J]. Tumori, 2000, 86(5): 403-407.
[21] Roberti MP, Mordoh J, Levy EM.Biological role of NK cells and immunotherapeutic approaches in breast cancer[J]. Front Immunol, 2012, 3: 375.
[22] Shanker A, Marincola FM.Cooperativity of adaptive and innate immunity: implications for cancer therapy[J]. Cancer Immunol Immunother, 2011, 60(8): 1061-1074.
[23] Kondo E, Koda K, Takiguchi N, et al.Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer[J]. Dig Surg, 2003, 20(5): 445-451.
[24] Vaquer S, Jordá J, López de la Osa E, et al. Clinical implications of natural killer (NK) cytotoxicity in patients with squamous cell carcinoma of the uterine cervix[J]. Gynecol Oncol, 1990, 36(1): 90-92.
[25] Verma C, Kaewkangsadan V, Eremin JM, et al.Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery[J]. J Transl Med, 2015, 13: 180.
[26] Guo X, Fan Y, Lang R, et al.Tumor infiltrating lymphocytes differ in invasive micropapillary carcinoma and medullary carcinoma of breast[J]. Mod Pathol, 2008, 21(9): 1101-1107.
[27] Aaltomaa S, Lipponen P, Eskelinen M, et al.Lymphocyte infiltrates as a prognostic variable in female breast cancer[J]. Eur J Cancer, 1992, 28a(4-5): 859-864.
[28] Yamaguchi R, Tanaka M, Yano A, et al.Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer[J]. Hum Pathol, 2012, 43(10): 1688-1694.
[29] Eckl J, Buchner A, Prinz PU, et al.Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging[J]. J Mol Med (Berl), 2012, 90(1): 55-66.
[30] Platonova S, Cherfils-Vicini J, Damotte D, et al.Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma[J]. Cancer Res, 2011, 71(16): 5412-5422.
[31] Li Y, Wei Y, He Q, et al.Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer[J]. Sci Rep, 2018, 8(1): 6223.
[32] Muraro E, Comaro E, Talamini R, et al.Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy[J]. J Transl Med, 2015, 13: 204.
[33] Baxevanis CN, Perez SA, Papamichail M.Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy[J]. Cancer Immunol Immunother, 2009, 58(3): 317-324.
[34] Carson WE, 3rd, Shapiro CL, Crespin TR, et al. Cellular immunity in breast cancer patients completing taxane treatment[J]. Clin Cancer Res, 2004, 10(10): 3401-3409.
[35] Kim R, Kawai A, Wakisaka M, et al.A potential role for peripheral natural killer cell activity induced by preoperative chemotherapy in breast cancer patients[J]. Cancer Immunol Immunother, 2019, 68(4): 577-585.
[36] Denkert C, Loibl S, Müller BM, et al.Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial[J]. Ann Oncol, 2013, 24(11): 2786-2793.
[37] Takeuchi H, Maehara Y, Tokunaga E, et al.Prognostic significance of natural killer cell activity in patients with gastric carcinoma: a multivariate analysis[J]. Am J Gastroenterol, 2001, 96(2): 574-578.
[38] Halama N, Braun M, Kahlert C, et al.Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines[J]. Clin Cancer Res, 2011, 17(4): 678-689.